Christopher Cole

LogiPharma 2026 in Vienna debuts interactive, hands-on formats and a two-track structure to boost collaboration, training, and real-time engagement for life sciences supply chains.

Pharma’s $372B M&A surge fights a $300B patent cliff, with firms relying on early-stage assets and Chinese innovation to fill gaps by 2030.

Even the threat of Greenland-related tariffs rattled drug supply chains and uncovered industry vulnerabilities to instability.